Adaptive Biotechnologies
Adaptive Biotechnologies Q2 Revenues Jump 83 Percent
Test volume for ClonoSeq, its assay for minimal residual disease monitoring in blood cancers, grew 75 percent year over year and 15 percent sequentially.
The firm is expanding its plans from a Crohn's disease test to a broader GI differential diagnostic and continues to expect to launch its Lyme disease assay by year-end.
GenomeWeb Index Falls Again in March, Led by 29 Percent Decline in Adaptive Biotech Stock
The GenomeWeb Index underperformed the Dow Jones and the Nasdaq, but outperformed the Nasdaq Biotechnology Index last month.
FDA Issues EUA for Adaptive Biotechnologies COVID-19 T-Cell Response Test
The test leverages immune repertoire sequencing technology to identify individuals who have had a recent or prior SARS-CoV-2 infection.
Feb 25, 2021
Feb 24, 2021
Adaptive Biotechnologies Q4 Revenues Rise 25 Percent
Nov 11, 2020
Nov 10, 2020
Adaptive Biotechnologies Q3 Revenues Grow 1 Percent
May 13, 2020
May 12, 2020